So having a representative population is really important. One part of that is being able to enroll more patients in the ...

In today’s ACT Brief, we explore how site initiation can be leveraged to improve early trial performance through demonstrated ...

By leveraging the Fresh Start Effect at site initiation and shifting from passive training to demonstrated readiness, ...

In today’s ACT Brief, we examine persistent barriers limiting cancer trial participation and emerging approaches to address ...

A structured data ownership model—rooted in ICH GCP principles, supported by MHRA and FDA interpretations, and documented in validated system specifications—will enable sponsors to maintain compliance ...

Unclear boundaries between investigator-controlled and sponsor-managed data in IRT systems are creating avoidable compliance risk, particularly around investigational product inventory and quality ...

In a new ACT video interview, Shanthi Sivendran, MD, MSCR, MBA, senior vice president for cancer care support at the American ...

Explore early data from the ACTS program that reveal the volume and types of patient-reported barriers to cancer care and ...

Funding uncertainty, legal and political pressures, trade policy shifts, site collaboration strategies, and leadership perspectives were central themes across Applied Clinical Trials’ most-watched ...

Learn why combining AI-enabled trial matching with transportation, lodging, and financial assistance is essential to turning ...

Examine how the American Cancer Society’s national ACTS expansion is designed to simplify trial discovery, reduce logistical ...

Persistent recruitment delays, high dropout rates, and missed timelines continue to slow global clinical trials, while data show that sub-Saharan Africa offers a largely untapped opportunity with ...